Physician profile
Carol M Odegaard
NPI 1700876554
$821.69
in general payments reported to CMS, 2019-2025
14 companies · $205 in 2025
The $205 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $389 · 2020: $46.99 · 2023: $16.69 · 2024: $164 · 2025: $205.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $370 · Education: $16.27.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $369.55 |
| Education | $16.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $179.86 | 2019 | |
| Novo Nordisk INC | $109.41 | 2024-2025 | Ozempic, Rybelsus, Wegovy |
| Amgen INC. | $103.97 | 2019-2025 | Otezla, Repatha, Otezla |
| Exact Sciences Corporation | $98.06 | 2023-2025 | Cologuard Collection Kit |
| Pfizer INC. | $62.87 | 2019-2025 | |
| Kowa Pharmaceuticals America, INC. | $56.04 | 2019-2020 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $42.78 | 2024-2025 | Caplyta |
| Astrazeneca Pharmaceuticals LP | $34.62 | 2019-2025 | Airsupra |
| Amarin Pharma, INC. | $34.13 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $30.72 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $19.20 | 2019 | |
| Lilly USA, LLC | $18.36 | 2024 | Mounjaro, Zepbound |
| Sanofi Pasteur INC. | $18.25 | 2019 | |
| Glaxosmithkline, LLC. | $13.42 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Carol Odegaard listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.